Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials-Reference-Cited by-同舟云学术

Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials

Published:2024-02-23 Issue:3 Volume:33 Page:229-242
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Kiem Dominik¹,Ocker Matthias²³⁴^ORCID,Greil Richard¹⁵,Neureiter Daniel⁵⁶^ORCID,Melchardt Thomas¹⁵

Affiliation:

1. III Medical Department, Paracelsus Medical University, Salzburg, Austria

2. Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Campus, Charité Mitte, Charité University Medicine Berlin, Berlin, Germany

3. EO Translational Insights Consulting GmbH, Berlin, Germany

4. Tacalyx GmbH, Berlin, Germany

5. Cancer Cluster Salzburg, Salzburg, Austria

6. Institute of Pathology, Paracelsus Medical University, University Hospital Salzburg (SALK), Salzburg, Austria

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2024.2319317

Reference111 articles.

1. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

2. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

3. Aleem A Shah H. Atezolizumab: treasure island. (FL): StatPearls Publishing; 2023 [cited 2023 Jan 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567758/#

4. Agency EM. Tecentriq (atezolizumab): an overview of tecentriq and why it is authorised in the EU. 2022 [cited 2023 Nov 19]. Available from: https://www.ema.europa.eu/en/documents/overview/tecentriq-epar-medicine-overview_en.pdf

5. Agency EM. Imfinzi (durvalumab): an overview of imfinzi and why it is authorised in the EU. 2022 [cited 2023 Nov 19]. EMA/949093/2022 EMEA/H/C/004771. Available from: https://www.ema.europa.eu/en/documents/overview/imfinzi-epar-medicine-overview_en.pdf